Lilly exec says developing new therapies for lupus is 'in scope'

Max Bayer

Pharma Reporter

Despite prior setbacks, Lilly executives said they’re pressing ahead with new research in lupus at a time when other companies are taking to cell therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly exec says developing new therapies for lupus is 'in scope'

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Lil­ly ex­ec says de­vel­op­ing new ther­a­pies for lu­pus is 'in scope'

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lilly exec says developing new therapies for lupus is 'in scope'